The Artisan MAKEfile Platform utilizes its proprietary STAR-CRISPR system and suite of bioinformatics tools to optimize cell therapy targets. Through sophisticated on- and off-target profiling, Artisan produces a MAKEfile for CDMO execution.
Generative
Cell Design
Traversing the Generative Cell Design cycle at
scale for discovery, prototyping, and
optimization using proprietary CRISPR methods.
Artisan Bio Empowers Partners Throughout Discovery & Preclinical Development
SyionAI Delivers the Best Precision Therapeutic Targets
iPSC MAKEfiles
T Cell MAKEfiles
Artisan Bio provides partners with advanced genome engineering and drug discovery tools for the research and commercialization of cell and gene therapies.
“We are thrilled with the technical results and deep data produced by Artisan in our cell therapy engineering collaboration.
The Artisan Platform has the throughput, tools, assays, and skillsets required to rapidly optimize editing of target genes. Moreover, Artisan’s STAR-CRISPR platform proved powerful for rapidly identifying and tuning the best editing sites in the generation of multiplex edited product cells . Finally, Artisan’s many years of experience in gene editing, CRISPR nuclease discovery and engineering, as well as in cell engineering has thoroughly impressed our team at Takeda.”
Lan Cao Vice President Head of Cell Therapy Innovation
“Artisan has provided excellent delivery of proof-of-concept data using their genome engineering and STAR-CRISPR editing platform for gene knockout, as well as data for gene knock-in that is competitive with others in the field.
The quality and speed of their data generation, as well as their expanding suite of off target analyses to support potential clinical application, exceeded our expectations.
This technology offers an important path forward for gene editing to enable potential next generation cell therapy products.”
Gwen Binder Executive Vice President Science & Technology
Our team
Leadership Team
Over the past 2 decades, Ryan has envisioned and built a range of internationally recognized companies in the field of genome engineering. This includes roles as CEO, CSO, and Board Member at Inscripta, Inc.; founder at Biota Technology; and founder, advisor, and Board Member at OPXBIO. Ryan also has an outstanding academic history. He built a world-class synthetic biology/DNA Foundry group at the University of Colorado and was the Scientific Director and NNF Laureate Fellow for DNA Foundries at the Novo Nordisk Foundation Center for Biosustainablity in Denmark.
Ryan is the inventor on foundational patents for Artisan, as well as both Inscripta, Inc. and OPXBIO. Ryan’s scientific contributions include over 30 patents, 100+ peer reviewed publications, and dozens of invited and keynote presentations.
Tanya is the inventor on 20+ patent filings and brings deep expertise in genome engineering, DNA foundry workflows and automation, as well as engineering novel endonucleases for CRISPR-based editing.
Before joining Artisan, Paul served as CFO at Allvue Systems, a leading SaaS platform serving the alternative investment industry. Prior to Allvue, he held the position of Managing Director at Morgan Stanley where he led the financial technology investment banking team, advising clients globally on mergers and acquisitions, IPOs and other strategic transactions.
Paul holds a bachelor’s degree from the University of Notre Dame and a MBA from the University of Michigan.
Prior to founding Biota, Ajay was a venture capital investor in a $100M seed fund spun out from Mohr Davidow Ventures, XSeed Capital. The firm invested and formed companies based on university science innovations. Ajay began his career at the world-leading cancer therapeutic company Genentech, where he held various positions in product operations.
Ajay is an active member of YPO, a global organization for CEOs, where he serves on the Board of the Costal San Diego chapter and two Global networks, Deal and Entrepreneurship. He holds a B.S. in chemical engineering from U.C. Berkeley, an M.S. in engineering from Stanford University, and an MBA from Berkeley-Haas School of Business.
Board of Directors
Over the past 2 decades, Ryan has envisioned and built a range of internationally recognized companies in the field of genome engineering. This includes roles as CEO, CSO, and Board Member at Inscripta, Inc.; founder at Biota Technology; and founder, advisor, and Board Member at OPXBIO. Ryan also has an outstanding academic history. He built a world-class synthetic biology/DNA Foundry group at the University of Colorado and was the Scientific Director and NNF Laureate Fellow for DNA Foundries at the Novo Nordisk Foundation Center for Biosustainablity in Denmark.
Ryan is the inventor on foundational patents for Artisan, as well as both Inscripta, Inc. and OPXBIO. Ryan’s scientific contributions include over 30 patents, 100+ peer reviewed publications, and dozens of invited and keynote presentations.
Tanya is the inventor on 20+ patent filings and brings deep expertise in genome engineering, DNA foundry workflows and automation, as well as engineering novel endonucleases for CRISPR-based editing.
He started his career in the technology field and held management positions at Intel and Metaphor Computer Systems (later acquired by IBM). Chess served on the White House Staff in the first Bush Administration as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy. He is a lecturer at the Stanford Graduate School of Business, where he teaches courses in health care and entrepreneurship. Chess received a BS in engineering with honors from Caltech and an MBA from Harvard.
He is a member of the UC Berkeley School of Mechanical Engineering External Advisory Board and a lecturer in the Haas School of Business. He has served on several National Academy of Science / National Research Council steering committees and on the board of the Bay Area Council Economic Institute (BACEI). He currently serves on the board of trustees for the National Center for Women and Information Technology (NCWIT). He also serves on the RI2 Selection Committee at Caltech.
Michael led XSeed’s investments in and currently participates on the Boards of Artisan Bio, AtScale, Biota, Citrine Informatics, Enya.ai, Life Signals, Lilt, Mines.io, PeerWell and Widesense. He also led XSeed’s investments in Trifacta and Listo, as well as GeneWeave Biosciences (acquired by Roche – RHHBY), OPXBIO (acquired by Cargill, Inc.), Playnomics (acquired by Unity Technologies), BrightBox (acquired by Flextronics International Ltd – FLEX), Eloquent Labs (acquired by Square – SQ) and Allopartis (acquired by Novozymes – NVZMY).
Before founding XSeed in 2006, Michael was an Entrepreneur-in-Residence at Mohr Davidow Ventures. He also spent five years at a financial services start-up, was Adjunct Professor in UC Berkeley’s College of Engineering, and a partner in a strategy consulting firm. While at UC Berkeley, he co-founded the Berkeley Roundtable on the International Economy.
Michael has authored three books and 75 chapters, articles and monographs on topics including the internet and data networking, management of technology, competition in information technology industries, international trade and investment, and financial strategies for technology companies. The common thread in his varied careers has been a focus on emerging new technologies, and the business models and strategies necessary to exploit new market opportunities.
Advisory Board
He has also been responsible for the development and execution of an end-to-end vision and strategy for Pharmaceutical Sciences, ensuring the necessary capabilities for an innovative, highly partnered and modality-diverse pipeline. Pharmaceutical Sciences supports CMC activities through all development stages and is also responsible for Takeda’s device development. Stefan’s team is responsible for the seamless transfer of technology and know-how to the Global Manufacturing and Sciences and Global Quality organizations.
Prior to joining Takeda, Stefan worked at Novartis Pharma AG, where he was Vice President of Global Head Technical Research and Development Cell- and Gene-Therapies (TRD-CGT). While at Novartis, he and his teams were responsible for building the technical team, capabilities, internal and external footprint, as well as the strategy, that supported a variety of cell and gene therapy programs, delivering the cell process for the first ever approved and commercialized chimeric antigen receptor T cell (CAR-T) therapy. Before joining Novartis, he served as Head of Biologics and Bioprocess Research and Development at Merck & Co and Senior Director at Merck BioVentures (MBV), where he was a member of the core team developing Merck’s entry into the follow-on biologics space.
His research studies are aimed at developing cellular therapies to reduce leukemia recurrence by enhancing immune recovery and by more effectively treating sites of leukemia (with a newly developed method of bone marrow irradiation).
Dr. Brown received her doctoral degree from the University of California, Berkeley, and was a Leukemia & Lymphoma Scholar during her post-doctoral fellowship at Pennsylvania State University. Her research has been published in New England Journal of Medicine, Science Translational Medicine, Cancer Discovery, Clinical Cancer Research, and other notable journals, as well as featured by many news and magazine outlets including National Public Radio (NPR), O Magazine and US News and World Report. Dr. Brown has more than ten patents in the CAR T cell field and her discoveries have been foundational for the start of two publically traded biotechnology companies.
One major focus of his lab is identifying novel ways that CAR cellular therapy can overcome the problem of antigen escape in order to fully eliminate disseminated, heterogeneous cancer cells. Additional problems exist in solid tumors, including poor penetration of the tumor by CAR-T cells, and inherent resistance of particular tumors to T cell killing. The mechanisms by which these occur, and methods to overcome them, are active areas of investigation within the laboratory.
His research is focused on the development of novel animal mouse models for use in evaluating CAR cellular therapies, the development of new CARs (i.e. not CD19) targeting a variety of hematologic and solid tumor malignancies, and the refining and optimization of the production of therapeutic tumor-infiltrating lymphocytes (TILs) for treatment of solid tumors.
Prior to GenApex Bio, Dr. Peterson was Chief Scientific Officer at the Allen Institute comprising foundational and applied research programs across its Brain Science, Cell Science, Immunology Institutes, and the Paul G. Allen Frontiers Group. Prior to the Allen Institute, Dr. Peterson was Chief Technology Officer at Synthetic Genomics (SGI) where he led an integrated team of scientists, engineers and informaticians to engineer diverse complex living systems. Before joining SGI, he led Synthetic Biology, Cloning and Protein Expression and Genomics R&D at Invitrogen/Life Technologies (now ThermoFisher), a global leader in life science research tools.
Dr. Peterson has held industrial R&D leadership and bench scientist positions with increasing responsibilities at Genicon Sciences, Trega Biosciences, Hybritech, Gen-Probe and Immulok, focusing on technology development and product commercialization. Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne, Germany, received his Ph.D. in Microbiology at the University of Southern California School of Medicine, and received his M.A. in Biological Sciences and his B.A. in Molecular Biology and Biochemistry from the University of California, Santa Barbara.
Nielsen is applying system analysis and design to tissue engineering including novel strategies for generating microtissues for drug screening, and using stem cells to produce red and white blood cells for transfusion. Nielsen has been granted patents in the fields of stem cells and metabolic engineering. He was on the Scientific Advisory Board of InSphero from 2009–2015, a company commercializing microtissue technology originating in the Nielsen laboratory. He is an editorial board member of a wide variety of scientific journals and holds several major awards in his field.
Palsson’s research includes the development of methods to analyze metabolic dynamics (flux-balance analysis, and modal analysis), and the formulation of complete models of selected cells (the red blood cell, E. coli, CHO cells, and several human pathogens). He sits on the editorial broad of several leading peer-reviewed microbiology, bioengineering, and biotechnology journals. Palsson is the author of over 40 U.S. patents, the co-founder of several biotechnology companies, and holds several major biotechnology awards.